Zobrazeno 1 - 10
of 94
pro vyhledávání: '"John G. Watkin"'
The new compounds [Nb(η-C6H5Me)(PMe3)3R](R = H or SiMe3), [Nb(η-C6H5Me)(tmps)], [Nb(η-C6H5Me)(tmps)H][tmps = MeSi(CH2PMe2)3], [Nb(η-C6H5Me)(η-C5H5)(PMe3)], [Nb(η-C6H5Me)(η-C9H7)(PMe3)], [Nb(η5-C9H7)(CO)3(PMe3)], [Nb(η-C6H5Me)(η5-C7H9)(PMe3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122d63a64c09a5c52cb241b423a3bd7f
https://doi.org/10.1039/dt9910001705
https://doi.org/10.1039/dt9910001705
Publikováno v:
Pain Medicine. 8:397-409
Indianapolis, Indiana, USA ABSTRACT Objective. The current analysis examines the response profile in patients receiving duloxetine for the management of diabetic peripheral neuropathic pain (DPNP). Patients/Design. Data were pooled from three double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4f3e110f43b613abbe4d0ce1bfafe7
https://doi.org/10.1111/j.1526-4637.2007.00305.x
https://doi.org/10.1111/j.1526-4637.2007.00305.x
Autor:
Craig H. Mallinckrodt, B A Apurva Prakash, Madelaine M. Wohlreich, William P. Carter, John G. Watkin
Publikováno v:
Depression and Anxiety. 24:41-52
Duloxetine has demonstrated efficacy for the treatment of major depressive disorder (MDD) at a dose of 60 mg/day (given once daily). Whereas the target dose for the majority of patients is 60 mg/day, higher duloxetine doses (up to 120 mg/day) have be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f61c9dd0f00d0be26a9a1b280a5862
https://doi.org/10.1002/da.20209
https://doi.org/10.1002/da.20209
Autor:
Maurizio Fava, Madelaine M. Wohlreich, Apurva Prakash, Craig H. Mallinckrodt, John G. Watkin, James M. Martinez
Publikováno v:
Journal of Clinical Psychopharmacology. 25:552-560
This study compared the stabilized duloxetine dose through approximately 12 weeks of treatment in patients initiating duloxetine therapy with that in patients switching to duloxetine from selective serotonin reuptake inhibitors or venlafaxine. All pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d3fce4d98dc4edbd681203334249c0
https://doi.org/10.1097/01.jcp.0000185429.10053.c8
https://doi.org/10.1097/01.jcp.0000185429.10053.c8
Autor:
Craig H. Mallinckrodt, Maurizio Fava, John G. Watkin, Madelaine M. Wohlreich, David L. Dunner
Publikováno v:
Current Therapeutic Research. 66(6):522-540
Background:To reduce the risk for treatment-emergent adverse events and increase patient compliance, clinicians frequently prescribe a suboptimal starting dose of antidepressants, with the goal of increasing the dose once the patient has demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8247bde47a3f87f05ef48d7fdbb45a5
Autor:
Michael G. Wilson, Pedro L. Delgado, Craig H. Mallinckrodt, John G. Watkin, Maurizio Fava, John H. Greist, Madelaine M. Wohlreich
Publikováno v:
Annals of Clinical Psychiatry. 17:259-268
Approximately half of all treated depressed patients fail to show adequate response to their initially prescribed antidepressant medication. Switching to another medication represents one possible next-step approach for nonresponsive or partially res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1841928d8f7cbadf5c90b76226247b5d
https://doi.org/10.1080/10401230500296402
https://doi.org/10.1080/10401230500296402
Autor:
Pierre V. Tran, Pedro L. Delgado, Michael J. Detke, Craig H. Mallinckrodt, Robert K. McNamara, John G. Watkin, Stephen K. Brannan, Fujun Wang
Publikováno v:
The Journal of Clinical Psychiatry. 66:686-692
OBJECTIVE The onset or worsening of sexual dysfunction is a common treatment-emergent side effect of antidepressant medications. Post hoc analyses of pooled data from placebo-controlled studies were utilized to assess sexual functioning in patients r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::befb30f50a59962f630f04c0b0239e0e
https://doi.org/10.4088/jcp.v66n0603
https://doi.org/10.4088/jcp.v66n0603
Autor:
Craig H. Mallinckrodt, John G. Watkin, J. Craig Nelson, Madelaine M. Wohlreich, Michael J. Detke, John S. Kennedy
Publikováno v:
The American Journal of Geriatric Psychiatry. 13:227-235
Objective The efficacy and safety of duloxetine, a dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE), were evaluated in the treatment of major depressive disorder (MDD) and associated pain symptoms in patients age 55 and older. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::115c8b2c9659d9a9d2aea2647abfa1b2
https://doi.org/10.1097/00019442-200503000-00008
https://doi.org/10.1097/00019442-200503000-00008
Publikováno v:
Pharmaceutical Statistics. 3:161-169
Missing data, and the bias they can cause, are an almost ever-present concern in clinical trials. The last observation carried forward (LOCF) approach has been frequently utilized to handle missing data in clinical trials, and is often specified in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89229d73defc3f22066a392c9500c358
https://doi.org/10.1002/pst.124
https://doi.org/10.1002/pst.124
Autor:
Christopher Kaiser, John G. Watkin, Michael J. Detke, Geert Molenberghs, Raymond J. Carroll, Craig H. Mallinckrodt
Publikováno v:
Pharmaceutical Statistics. 3:171-186
The last observation carried forward (LOCF) approach is commonly utilized to handle missing values in the primary analysis of clinical trials. However, recent evidence suggests that likelihood-based analyses developed under the missing at random (MAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f5ed2ef1ab7ea0455707a7df992fdfb
https://doi.org/10.1002/pst.131
https://doi.org/10.1002/pst.131